2',4'-dichloro-N-(3-(1-hydroxyethyl)phenyl)biphenyl-4-sulfonamide | 1218932-01-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2',4'-dichloro-N-(3-(1-hydroxyethyl)phenyl)biphenyl-4-sulfonamide
• 英文别名: 4-(2,4-dichlorophenyl)-N-[3-(1-hydroxyethyl)phenyl]benzenesulfonamide
• CAS: 1218932-01-4
• 化学式: C₂₀H₁₇Cl₂NO₃S
• 分子量: 422.332
• InChiKey: IBAUZZODDLUVQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-(3-acetylphenyl)-2',4'-dichlorobiphenyl-4-sulfonamide 在 甲醇 、 sodium tetrahydroborate 作用下， 反应 16.0h， 生成 2',4'-dichloro-N-(3-(1-hydroxyethyl)phenyl)biphenyl-4-sulfonamide
  参考文献：
  名称：

  [EN] ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE
  [FR] COMPOSÉS ARYL-PHÉNYL-SULFONAMINO-PHÉNYLÈNE ET LEURS UTILISATIONS

  摘要：

  本发明通常涉及治疗化合物领域，更具体地涉及以下式(I)的某些芳基苯磺酰胺基苯基化合物（以下统称为“APSAP化合物”）。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体内外的使用，例如用于治疗炎症和/或关节破坏和/或骨质流失；过度和/或不适当和/或持续激活免疫系统的疾病；炎症性和自身免疫性疾病，例如类风湿关节炎、牛皮癣、银屑病性关节炎、慢性阻塞性肺病（COPD）、动脉粥样硬化、炎症性肠病、强直性脊柱炎等；与骨质流失相关的疾病，例如类风湿性关节炎中与过度破骨细胞活性相关的骨质流失、骨质疏松症、癌症相关骨病、帕吉特病等；以及癌症，如血液系统恶性肿瘤、实体肿瘤等。

  公开号：

  WO2010032010A1

文献信息

• [EN] N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE<br/>[FR] N-(4-HYDROXY-4-MÉTHYLCYCLOHEXYL)-4-PHÉNYLBENZÈNESULFONAMIDES ET N-(4-HYDROXY-4-MÉTHYLCYCLOHEXYL)-4-(2-PYRIDYL)BENZÈNESULFONAMIDES ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：PIMCO 2664 LTD

  公开号：WO2014207445A1

  公开（公告）日：2014-12-31

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4- methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl- cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and / or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

  本发明涉及治疗化合物领域。更具体地，本发明涉及某些取代的N-(4-羟基-4- 甲基环己基)-4-苯基-苯磺酰胺和N-(4-羟基-4-甲基环己基)-4-(2-吡啶基)苯磺酰胺化合物（以下统称为HMC化合物），该化合物可用于治疗包括炎症和/或关节破坏和/或骨质流失等疾病的治疗，由过度和/或不适当和/或持续激活免疫系统引起的疾病；炎症性和自身免疫性疾病，例如类风湿性关节炎；牛皮癣；银屑病性关节炎；慢性阻塞性肺病（COPD）；哮喘；动脉粥样硬化；炎症性肠病；强直性脊柱炎；多发性硬化症；系统性红斑狼疮；干燥综合症；与骨质流失有关的疾病，例如类风湿性关节炎中与过度破坏骨细胞活性有关的骨质流失，骨质疏松症，癌症相关骨病或Paget病；癌症，如血液恶性肿瘤，如多发性骨髓瘤，白血病或淋巴瘤，或实体肿瘤癌，如膀胱癌，乳腺癌（女性和/或男性），结肠癌，肾细胞癌，肾癌，肺癌，胰腺癌，胃癌，前列腺癌，脑癌，皮肤癌，甲状腺癌，基底细胞颌骨癌或黑色素瘤；与纤维化有关的疾病，如系统性硬化症或硬皮病；或罕见的血管炎，如Behçet病。本发明还涉及包含这种化合物的药物组合物，以及这种化合物和组合物的用途，例如在治疗中的应用。
• [EN] N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE<br/>[FR] N-(4-HYDROXY-4-MÉTHYLCYCLOHEXYL)-4-PHÉNYLBENZÈNESULFONAMIDES ET N-(4-HYDROXY-4-MÉTHYLCYCLOHEXYL)-4-(2-PYRIDYL)BENZÈNESULFONAMIDES ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：PIMCO 2664 LTD

  公开号：WO2016097001A1

  公开（公告）日：2016-06-23

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4- methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl- cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and / or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

  本发明涉及治疗化合物领域。更具体地，本发明涉及某些取代的N-(4-羟基-4-甲基-环己基)-4-苯基-苯磺酰胺和N-(4-羟基-4-甲基-环己基)-4-(2-吡啶基)苯磺酰胺化合物（以下统称为HMC化合物），例如用于治疗炎症和/或关节破坏和/或骨质流失等疾病；由免疫系统过度和/或不适当和/或持久激活引起的疾病；炎症和自身免疫性疾病，例如类风湿性关节炎；牛皮癣；银屑病性关节炎；慢性阻塞性肺疾病（COPD）；哮喘；动脉粥样硬化；炎症性肠病；强直性脊柱炎；多发性硬化症；全身性红斑狼疮；Sjogren综合征；与骨质流失有关的疾病，例如与类风湿性关节炎、骨质疏松症、癌症相关骨病或Paget病中过度破骨细胞活动有关的骨质流失；癌症，例如血液恶性肿瘤，例如多发性骨髓瘤、白血病或淋巴瘤，或实体肿瘤癌症，例如膀胱癌、乳腺癌（女性和/或男性）、结肠癌、肾细胞癌、肾癌、肺癌、胰腺癌、胃癌、前列腺癌、脑癌、皮肤癌、甲状腺癌、基底细胞颌骨瘤或黑色素瘤；与纤维化有关的疾病，例如系统性硬化或硬皮病；或罕见的血管炎，例如Behçet病。本发明还涉及包含此类化合物的制药组合物，以及这些化合物和组合物的使用，例如用于治疗。
• Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use
  申请人：Greig Iain Robert

  公开号：US20110190302A1

  公开（公告）日：2011-08-04

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as “APSAP compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.

  本发明涉及治疗化合物领域，更具体地涉及以下公式（I）的某些芳基-苯基-磺酰胺基-苯基化合物（以下统称为“APSAP化合物”）。本发明还涉及包含这些化合物的制药组合物，以及这些化合物和组合物的使用，无论是在体外还是体内，用于治疗炎症和/或关节破坏和/或骨质流失；治疗由免疫系统过度和/或不适当和/或持续激活引起的疾病；治疗炎症和自身免疫性疾病，例如类风湿性关节炎、牛皮癣、银屑病性关节炎、慢性阻塞性肺疾病（COPD）、动脉粥样硬化、炎性肠病、强直性脊柱炎等；治疗与骨质流失有关的疾病，例如类风湿关节炎中过度破骨细胞活动引起的骨质流失、骨质疏松症、癌症相关骨病、帕吉特病等；以及治疗癌症，例如血液系统恶性肿瘤、实体瘤等。
• N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE
  申请人：PIMCO 2664 LIMITED

  公开号：US20160145206A1

  公开（公告）日：2016-05-26

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

  本发明涉及治疗化合物领域。更具体地，本发明涉及某些取代的N-(4-羟基-4-甲基-环己基)-4-苯基-苯磺酰胺和N-(4-羟基-4-甲基-环己基)-4-(2-吡啶基)苯磺酰胺化合物（以下统称为HMC化合物），例如在治疗疾病中有用，包括炎症和/或关节破坏和/或骨质流失的疾病；由免疫系统过度和/或不适当和/或持续激活介导的疾病；炎症和自身免疫性疾病，例如类风湿性关节炎；银屑病；银屑病性关节炎；慢性阻塞性肺疾病（COPD）；哮喘；动脉粥样硬化；炎症性肠病；强直性脊柱炎；多发性硬化症；系统性红斑狼疮；Sjogren综合症；与骨质流失有关的疾病，例如与类风湿性关节炎，骨质疏松症，癌症相关骨病或Paget病中过度破骨细胞活性有关的骨质流失；癌症，例如血液恶性肿瘤，例如多发性骨髓瘤，白血病或淋巴瘤，或实体肿瘤癌，例如膀胱癌，乳腺癌（女性和/或男性），结肠癌，肾细胞癌，肾癌，肺癌，胰腺癌，胃癌，前列腺癌，脑癌，皮肤癌，甲状腺癌，基底细胞上皮瘤或黑色素瘤；与纤维化有关的疾病，例如系统性硬化或硬皮病；或罕见的血管炎，例如Behçet病。本发明还涉及包含这种化合物的制药组合物以及这种化合物和组合物的使用，例如在治疗中。
• N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
  申请人：PIMCO 2664 LIMITED

  公开号：US10029979B2

  公开（公告）日：2018-07-24

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumor cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

  本发明一般涉及治疗化合物领域。更具体地说，本发明涉及某些取代的 N-(4-羟基-4-甲基-环己基)-4-苯基苯磺酰胺和 N-(4-羟基-4-甲基-环己基)-4-(2-吡啶基)苯磺酰胺化合物（在此统称为 HMC 化合物），这些化合物可用于治疗各种疾病（例如疾病），包括炎症和/或关节破坏和/或骨质流失；免疫系统过度和/或不适当和/或长期激活引起的疾病；炎症和自身免疫性疾病，例如类风湿性关节炎；银屑病；银屑病关节炎；慢性阻塞性肺疾病（COPD）；哮喘；动脉粥样硬化；炎症性肠病；强直性脊柱炎；多发性硬化症；系统性红斑狼疮；斯约格伦综合征；与骨质流失有关的疾病，如类风湿性关节炎、骨质疏松症、癌症相关骨病或帕吉特氏病中与破骨细胞过度活动有关的骨质流失；癌症，如血液恶性肿瘤，如多发性骨髓瘤、白血病或淋巴瘤，或实体瘤癌症，如膀胱癌、乳腺癌（女性和/或男性）、结肠癌、肾细胞癌、肾癌、肺癌、胰腺癌、胃癌、前列腺癌、脑癌、皮肤癌、甲状腺癌、基底细胞母细胞瘤或黑色素瘤；与纤维化相关的疾病，如系统性硬化症或硬皮病；或罕见的血管性疾病，如白塞氏病。本发明还涉及包含此类化合物的药物组合物，以及此类化合物和组合物在治疗等方面的用途。